Dr. Michael W. Cammarata, MD
Interventional Cardiology (Interventional Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,536
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Florida College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
FL license ME130392 -
Cardiovascular Disease Physician
FL license ME130392 -
Internal Medicine Physician
NC license 2010-02070
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boca Raton Regional Hospital Boca Raton, FL
- Delray Medical Center Delray Beach, FL
- HCA Florida Jfk Hospital Atlantis, FL
Medical groups
- Boca Raton Ekg Readers Inc (24 clinicians)
- Bartzokis Rubenstein Servoss MD Pl (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,536
- Services billed
- 6,861
- Patients’ average age
- 80
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,255 | 778 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 838 | 755 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 568 | 562 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 539 | 67 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 516 | 61 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 475 | 229 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 437 | 308 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 372 | 186 |
| Injection, regadenoson, 0.1 mg | 336 | 84 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 186 | 186 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Boca Raton, FL | 313 |
| Eliquis (apixaban) Other prescribers in Boca Raton, FL | 214 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Boca Raton, FL | 212 |
| Atorvastatin Calcium Other prescribers in Boca Raton, FL | 184 |
| Metoprolol Succinate Other prescribers in Boca Raton, FL | 172 |
| Nebivolol Hcl Other prescribers in Boca Raton, FL | 155 |
| Amlodipine Besylate Other prescribers in Boca Raton, FL | 141 |
| Repatha Sureclick (evolocumab) Other prescribers in Boca Raton, FL | 120 |
| Furosemide Other prescribers in Boca Raton, FL | 97 |
| Losartan Potassium Other prescribers in Boca Raton, FL | 92 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 102 payments worth $3,057 in total to this clinician.
| Abbott Laboratories | $1,896 |
|---|---|
| Novartis Pharmaceuticals Corporation | $247 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $194 |
| Boston Scientific Corporation | $166 |
| Pfizer Inc. | $132 |
| Kestra Medical Technology Services, Inc. | $64.76 |
| Merck Sharp & Dohme LLC | $55.37 |
| Alnylam Pharmaceuticals Inc. | $34.66 |
| Food and Beverage | $1,822 |
|---|---|
| Travel and Lodging | $1,235 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Abbott Laboratories Jun 23, 2025 | Travel and Lodging TRICLIP · Structural Heart · travel to Los Angeles, CA · in-kind | $730 |
| Abbott Laboratories Jun 18, 2025 | Travel and Lodging TRICLIP · Structural Heart · travel to Los Angeles, CA · in-kind | $395 |
| Abbott Laboratories Jun 18, 2025 | Travel and Lodging TRICLIP · Structural Heart · travel to Los Angeles, CA · in-kind | $100 |
| Abbott Laboratories Jun 23, 2025 | Travel and Lodging TRICLIP · Structural Heart · travel to Los Angeles, CA · in-kind | $9.02 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $84,121 in research payments for these studies, mostly to the institutions running them.
- ALLEVIATE-HF
Medtronic, Inc. - A phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of muvalaplin on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) who have had a prior…
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.